VYNE Therapeutics to merge with Yarrow Bioscience; Yarrow stockholders to own ~97% of combined company

VYNE Therapeutics Inc.

Pro forma ownership: pre-Merger Yarrow stockholders ~97%, VYNE stockholders ~3%.
Pre-Closing Dividend of ~$14.5M to $16.5M to VYNE stockholders prior to close.
Two concurrent financings: Yarrow Series A preferred ~$100M and Pre-Closing PIPE ~$100M.
Expected close Q2 2026; post-close board and officers designated by Yarrow.

item 1.01 item 3.02 item 5.01 item 5.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.